Edwin P Alyea
Overview
Explore the profile of Edwin P Alyea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
6146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bachireddy P, Azizi E, Burdziak C, Nguyen V, Ennis C, Maurer K, et al.
Cell Rep
. 2023 Aug;
42(8):113011.
PMID: 37556329
No abstract available.
2.
Whangbo J, Nikiforow S, Kim H, Wahl J, Reynolds C, Rai S, et al.
Blood Adv
. 2022 Apr;
6(21):5786-5796.
PMID: 35475885
Chronic graft-versus-host disease (cGVHD) remains a frequent cause of nonrelapse morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Despite recent advances, options for steroid-refractory (SR) cGVHD are limited. In...
3.
Murdock H, Kim H, Denlinger N, Vachhani P, Hambley B, Manning B, et al.
Blood
. 2022 Mar;
139(24):3546-3557.
PMID: 35286378
Older patients with acute myeloid leukemia (AML) have high relapse risk and poor survival after allogeneic hematopoietic cell transplantation (HCT). Younger patients may receive myeloablative conditioning to mitigate relapse risk...
4.
Ho V, Kim H, Brock J, Galinsky I, Daley H, Reynolds C, et al.
Blood Adv
. 2021 Nov;
6(7):2183-2194.
PMID: 34807983
Vaccination using irradiated, adenovirus transduced autologous myeloblasts to secrete granulocyte-macrophage colony-stimulating factor (GVAX) early after allogeneic hematopoietic stem cell transplantation (HSCT) can induce potent immune responses. We conducted a randomized...
5.
Bachireddy P, Azizi E, Burdziak C, Nguyen V, Ennis C, Maurer K, et al.
Cell Rep
. 2021 Nov;
37(6):109992.
PMID: 34758319
To elucidate mechanisms by which T cells eliminate leukemia, we study donor lymphocyte infusion (DLI), an established immunotherapy for relapsed leukemia. We model T cell dynamics by integrating longitudinal, multimodal...
6.
Kim H, Baker P, Parry E, Davids M, Alyea E, Ho V, et al.
Haematologica
. 2021 Aug;
106(12):3219-3222.
PMID: 34435483
No abstract available.
7.
Vartanov A, Lampson B, Jacobsen E, Alyea E, Moslehi J, Brown J
HeartRhythm Case Rep
. 2021 Jul;
7(6):391-394.
PMID: 34194987
No abstract available.
8.
Dillon L, Gui G, Logan B, Fei M, Ghannam J, Li Y, et al.
JCO Precis Oncol
. 2021 May;
5.
PMID: 34036237
Purpose: Patients with myelodysplastic syndrome (MDS) are at risk of relapse after allogeneic hematopoietic cell transplantation. The utility of ultra-deep genomic testing to predict and the impact of conditioning intensity...
9.
Luo Z, Domenech-Estarellas E, Han A, Lee D, Khatri R, Wahl J, et al.
Transplant Cell Ther
. 2021 May;
27(5):433.e1-433.e8.
PMID: 33942724
There is no Food and Drug Administration-approved treatments for ocular chronic graft-versus-host disease (oGVHD) to date, and current therapeutic options are limited. Forehead application of 1% progesterone gel provides corneal...
10.
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide
Rambaldi B, Kim H, Reynolds C, Rai S, Arihara Y, Kubo T, et al.
Blood Adv
. 2021 Jan;
5(2):352-364.
PMID: 33496734
Administration of posttransplant cyclophosphamide (PTCy) has significantly expanded the number of patients undergoing HLA-haploidentical hematopoietic cell transplantation (haplo-HCT). To examine immune reconstitution in these patients, we monitored T- and natural...